(MedPage Today) -- The FDA approved the small-molecule inhibitor pimicotinib (Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) and high surgical risk. An oral selective inhibitor of colony stimulating factor...
The weekly brief
One email a week: the clinical, policy and industry stories that moved medicine, with the source links.
News, not medical advice. Nothing here is a diagnosis, a treatment recommendation, or a substitute for a licensed clinician.
Facts from this channel's live bundle.
FDA approves another option for a rare benign soft-tissue tumor. Next-generation anticoagulant wins FDA nod for secondary stroke prevention. New Medicare payment model for back pain and heart failure draws physician pushback. Novel ADC boosts survival in pretreated endometrial cancer; CAR-T shows mixed results in rheumatoid arthritis. Another drug shows potential for functional cures in chronic hepatitis B.
Doximity is expanding its clinical AI footprint to more than 190 health systems. The company is also positioning clinical reliability as a competitive focus, launching DoseCheck and a partnership with Wolters Kluwer's UpToDate.
(MedPage Today) -- Reductions in hepatitis B surface antigen (HBsAg) were observed with a novel small interfering RNA (siRNA) therapy in patients with chronic hepatitis B virus (HBV) infection, according to a phase II study. Among patients randomized...
Mayo Clinic Platform launched an AI-driven clinical decision support tool. Beginning in November, eligible clinicians will get a specialty-specific chat covering more than 35 specialties plus 22 clinical calculators available via chat or voice dictation.
(MedPage Today) -- Results from the TroFuse-005 trial presented at the annual European Society for Medical Oncology congress showed that the investigational antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) significantly improved...
Brepocitinib produced dramatic improvement in patients with cutaneous sarcoidosis, a condition lacking any very effective therapy, in a small phase II trial presented in Orlando. The dual-acting TYK2/JAK1 inhibitor, marketed as Lisraya, was tested in a trial the excerpt describes only as small, without giving a patient count or effect size.
Federal Medicare regulators have finalized rules codifying the drug price negotiation framework created by the Inflation Reduction Act. The action locks in that framework while drugmakers continue to press repeated legal challenges in court.
A practical framework for assessing AI governance, evidence, transparency and post-deployment performance in clinical workflows.
(MedPage Today) -- A sham-controlled trial showed that sleeping while using high‑efficiency particulate air (HEPA) filters in the bedroom improved blood sugar control, as highlighted by NYU Langone Health. A smartwatch artificial intelligence...
Regulators approved asundexian, marketed as Sunharbo, as the first factor XIa inhibitor for secondary stroke prevention. The FDA announced the decision on Monday; the drug is an oral, direct, small-molecule inhibitor of FXIa. The excerpt does not state how this changes care for patients.
Researchers reported mixed results from a trial testing CAR T-cell therapy in rheumatoid arthritis. Data presented at a conference in Orlando suggested RA responds less consistently to the approach than lupus and certain other autoimmune conditions have.
Google Cloud released Gemini for healthcare, developed with clinical and health plan leaders. The company says the platform is built to support HIPAA compliance.
Three bladder cancer experts discussed emerging enfortumab vedotin-based treatment data at the ESMO congress in an exclusive roundtable. The discussion centered on muscle-invasive bladder cancer and the latest data presented at the meeting.
The weekly brief
One email a week with the stories that moved this field, plus what to watch next.
Fields marked * are required.
